Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely to meet the study’s primary endpoint. | Genentech has ...

Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in ...

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle ...

Genentech recently announced a series of marketing leadership hires to start off the new year. The biotech company hired Erica Taylor, PhD, as the company’s first chief marketing officer and tabbed ...

Genentech is honing in on an aspect of the patient community that is too often overlooked — the role of caregivers in managing rare diseases. In a recently-released short film, Genentech tells the ...

- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...

Biotechnology company Genentech is expanding its local manufacturing capabilities with a $450 million investment in its Oceanside campus. Genentech was founded in 1976 and has been considered a ...

- FENhance 1 is the final study readout of the fenebrutinib pivotal clinical development program in MS, following positive results for FENhance 2 in RMS and for FENtrepid in primary progressive ...

How is AI transforming the world’s original biotech company? Genentech is an American biotechnology corporation headquartered ...